Author

Ashley Young

Institutions: AdventHealth Orlando, AdventHealth

Observed institutions: AdventHealth Orlando, AdventHealth

OpenAlex ID: A5102254192

Phase II trial of lurbinectedin combined with avelumab as maintenance therapy for metastatic urothelial carcinoma with stable or responding disease following platinum-based chemotherapy.

2023 · Guru P. Sonpavde, Carlos A. Alemany, et al. · Journal of Clinical Oncology · 3

2019 Health Equity Summer Research Summit Organized by the Center of Excellence in Health Equity, Training and Research, Baylor College of Medicine, Houston, Texas 77030, USA on June 18th, 2019

2020 · A Uribe-Gomez, Abraham A. Salinas-Miranda, et al. · International Journal of Maternal and Child Health and AIDS · 1

Circulating tumor DNA (ctDNA) to predict response to neoadjuvant chemotherapy (NAC) and prognosis in patients (pts) with early breast cancer (BC).

2024 · Wassim McHayleh, Ashley Young, et al. · Journal of Clinical Oncology

Abstract PO4-15-12: Personalized circulating tumor DNA monitoring to predict response to neoadjuvant therapy in patients with early-stage breast cancer

2024 · Mridula George, Trishala Meghal, et al. · Cancer Research

Works count: 4

Citation count: 4

H-index: 1

I10-index: